Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer

The Cleveland Clinic220 enrolled

Overview

This study aims to evaluate the performance of serum free fatty acids as biomarkers for the identification of lung cancer.

We will compare the concentration of free fatty acids and their metabolites between patients with lung cancer and control pulmonary patients without known cancer. The diagnostic accuracy will be assessed for potential predictors.

Study Type

OBSERVATIONAL

Enrollment

220

Conditions

Lung Cancer Biomarkers Fatty Acids

Interventions

serum sampleOTHER

Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age from 40 to 80 * Lung adenocarcinoma with pathological diagnosis * Lung squamous cell carcinoma with pathological diagnosis * Control patients should have at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD. Exclusion Criteria: \- Lung cancer patient without serum sample before the initiation of treatment

Locations (1)

Cleveland Clinic

Cleveland, Ohio, United States

Outcomes

Primary Outcomes

Compare Concentration of Fatty Acids and Their Metabolites

Biochemical analysis of serum sample was conducted by an investigator who was strictly blinded to cancer status and patient characteristics.

Time frame: At the time of diagnosis, prior to the initiation of lung cancer treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.